Parmax Pharma
Parmax Pharma Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Parmax Pharma
Start SIPParmax Pharma Investment Rating
-
Master Rating:
-
Parmax Pharma has an operating revenue of Rs. 17.20 Cr. on a trailing 12-month basis. An annual revenue de-growth of -16% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -1% is poor and needs improvement. The company has a debt to equity of 76%, which is bit higher. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 19 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 4 | 1 | 6 | 5 | 2 | 2 | 7 |
| Operating Expenses Qtr Cr | 5 | 2 | 6 | 3 | 2 | 2 | 6 |
| Operating Profit Qtr Cr | -1 | -1 | 1 | 2 | 0 | -1 | 1 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit Qtr Cr | -1 | -1 | 0 | 2 | -1 | -1 | 0 |
Parmax Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 2
- Bearish Moving Average
- ___
- 14
- 20 Day
- ₹30.83
- 50 Day
- ₹30.67
- 100 Day
- ₹30.66
- 200 Day
- ₹31.49
- 20 Day
- ₹31.02
- 50 Day
- ₹30.62
- 100 Day
- ₹30.40
- 200 Day
- ₹30.80
Parmax Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 31.60 |
| Second Resistance | 32.59 |
| Third Resistance | 33.29 |
| RSI | 48.77 |
| MFI | 47.34 |
| MACD Single Line | 0.13 |
| MACD | 0.05 |
| Support | |
|---|---|
| First Resistance | 29.91 |
| Second Resistance | 29.21 |
| Third Resistance | 28.22 |
Parmax Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,989 | 155,699 | 78.28 |
| Week | 1,118 | 96,741 | 86.53 |
| 1 Month | 1,580 | 136,583 | 86.45 |
| 6 Month | 1,278 | 105,678 | 82.71 |
Parmax Pharma Result Highlights
Parmax Pharma Synopsis
BSE-Medical-Diversified
Parmax Pharma is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 18.25 Cr. and Equity Capital is Rs. 4.45 Cr. for the Year ended 31/03/2022. Parmax Pharma Ltd. is a Public Limited Listed company incorporated on 02/11/1994 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24231GJ1994PLC023504 and registration number is 023504.| Market Cap | 11 |
| Sales | 17 |
| Shares in Float | 0.26 |
| No of funds | |
| Yield |
| Book Value | 2.33 |
| U/D Vol ratio | 0.9 |
| LTDebt / Equity | 76 |
| Alpha | 0.07 |
| Beta | -0.56 |
Parmax Pharma
| Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
|---|---|---|---|---|
| Promoters | 30.8% | 30.8% | 30.8% | 30.8% |
| Individual Investors | 65.43% | 65.42% | 65.38% | 65.36% |
| Others | 3.77% | 3.78% | 3.82% | 3.84% |
Parmax Pharma Management
| Name | Designation |
|---|---|
| Mr. Umang Alkesh Gosalia | Managing Director |
| Mr. Pramay A Chhatra | Independent Director |
| Ms. Ami R Shah | Independent Director |
Parmax Pharma Forecast
Price Estimates
Parmax Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-11-10 | Quarterly Results | |
| 2023-08-14 | Quarterly Results | |
| 2023-05-30 | Audited Results | |
| 2023-02-11 | Quarterly Results | |
| 2022-11-12 | Quarterly Results |
Parmax Pharma FAQs
What is Share Price of Parmax Pharma ?
Parmax Pharma share price is ₹30 As on 09 December, 2023 | 01:41
What is the Market Cap of Parmax Pharma ?
The Market Cap of Parmax Pharma is ₹11.5 Cr As on 09 December, 2023 | 01:41
What is the P/E ratio of Parmax Pharma ?
The P/E ratio of Parmax Pharma is -18.2 As on 09 December, 2023 | 01:41
What is the PB ratio of Parmax Pharma ?
The PB ratio of Parmax Pharma is 2 As on 09 December, 2023 | 01:41